29/04/2015 : Monitoring of infliximab and C-Reactive Protein can predict loss of response in inflammatory bowel disease

A study conducted at the Saint-Etienne University Hospital sustains the relevance of infliximab monitoring with LISA TRACKER kits and dosing of C-Reactive Protein (CRP) to predict loss of response in IBD patientsMonitoring of biotherapies with…

Continue Reading 29/04/2015 : Monitoring of infliximab and C-Reactive Protein can predict loss of response in inflammatory bowel disease

25/03/2015 : THERADIAG receives CE marking for its 10th biotherapy monitoring test

New addition to LISA TRACKER, the market’s most complete range of biotherapy monitoring kitsNew test in the field of auto-immune and inflammatory diseasesCroissy-Beaubourg and Montpellier, March 25, 2015 – Theradiag (ISIN: FR0004197747, Ticker: ALTER), a company…

Continue Reading 25/03/2015 : THERADIAG receives CE marking for its 10th biotherapy monitoring test

23/03/2015 : THERADIAG strong presence at 2015 JFHOD meeting

Four presentations sustaining the relevance of biotherapy monitoring using LISA TRACKER testsOral Presentation by Prof. X. Roblin on the predictive potential of pharmacological level testing associated with other biomarkersStrong interest and increasing use of biotherapy…

Continue Reading 23/03/2015 : THERADIAG strong presence at 2015 JFHOD meeting